Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GB001
- Development stage
- Phase 2
- Lead developer
- Gossamer Bio
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GB001 is an investigational oral small molecule developed by Gossamer Bio. It functions as a potent and highly selective antagonist of the prostaglandin D2 receptor (DP2), also known as CRTH2. This mechanism aims to inhibit the recruitment and activation of airway eosinophils, thereby reducing inflammation. It was being developed as an add-on maintenance treatment for moderate-to-severe uncontrolled asthma and was also investigated for chronic rhinosinusitis. Gossamer Bio acquired the rights to GB001 through the acquisition of AA Biopharma and its subsidiary Pulmagen Therapeutics (Asthma) Limited in 2018.
- Other names
- ADC3680BADC-3680BADC 3680B
02
Targets
PTGDR2 (Prostaglandin D2 receptor 2)
Beyond the preview
Go deeper on GB001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GB001.